News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trius Therapeutics Decreases Size of IPO Deal from $78M to $49M


8/3/2010 7:17:55 AM

SAN DIEGO, Aug. 3 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing innovative antibiotics for serious, life-threatening infections, announced today the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The common stock is expected to begin trading on the NASDAQ Global Market on August 3, 2010 under the trading symbol "TSRX." Trius has granted the underwriters a 45 day option to purchase up to 750,000 shares of its common stock at the initial public offering price to cover over-allotments, if any.

Citigroup Global Markets Inc. is acting as sole book-running manager, Piper Jaffray & Co. is acting as co-lead manager and Canaccord Genuity Inc. and JMP Securities are acting as co-managers for the offering.

The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from Citigroup Global Markets Inc., Prospectus Department, Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220 or by calling 877-858-5407. The Securities and Exchange Commission declared a registration statement relating to these securities effective on August 2, 2010. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's first product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by MRSA. In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by bacteria of the gram-negative and gram-positive categories. For more information, visit www.triusrx.com.

SOURCE Trius Therapeutics, Inc.




comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES